Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant, P01375, 7124) CAS#: 103-0122-1816

Official Full Name Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
Squence Squence of Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant
Amino Acid Sequence MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F
Synonyms Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin
Accession Number P01375
GeneID 7124
Summary The clinical use of the potent antitumor activity of TNF-alphahas been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-alphamutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-alpha, which binds to the murine TNF-R55 but not to the murine TNF-R75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-alpha, which binds to both murine TNF receptors. Based on these results, many TNF-alphamutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.
Source Escherichia coli.
Molecular Weight Approximately 16.9 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, rHuTNF-α Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo.
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg in the presence of actinomycin D.
Appearance Sterile filtered white lyophilized (freeze-dried) powder.
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0.
Endotoxin Less than 1 EU/ug of rHu TNF-α/TNFSF2, Variant as determined by LAL method.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
SDS-PAGE SDS-PAGE of Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant
Safety Data Sheet (SDS) Download Click to download
Technical Data Sheet (TDS) Download Click to download

Buy Reagent

ChemWhat 140450210ug/100ug/500ug (> 98 % by SDS-PAGE and HPLC)
No reagent supplier? Send quick inquiry to ChemWhat
Want to be listed here as a reagent supplier? (Paid service) Click here to contact ChemWhat

Approved Manufacturers

Want to be listed as an approved manufacturer (Free service but requires approvement)? Please download and fill out this form and send back to approved-manufacturers@chemwhat.com

More Suppliers

Watson International Limited Send quick inquiry to Watson
Want to be listed here as a supplier? (Paid service) Click here to contact ChemWhat

Contact Us for Other Help

Contact us for other services like technology transfer, synthetic literature, sourcing, advertisement, etc. Click here to contact ChemWhat